Polyvalent Immunoglobulins Market Size, Share & Industry Analysis, By Product (PRIVIGEN, OCTAGAM, GAMMAGARD Liquid, Gamunex-C, Hizentra, XEMBIFY, and Others), By Indication (Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Immune Thrombocytopenic Purpura (ITP), Dermatomyositis, and Others), By Route of Administration (Intravenous, Subcutaneous, and Intramuscular), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, and Others), and Regional Forecast, 2026-2034

The global polyvalent immunoglobulins market size was valued at USD 15.20 billion in 2024 and is projected to reach USD 25.78 billion by 2032, exhibiting a CAGR of 7.1% during the forecast period. Polyvalent immunoglobulin is a therapeutic antibody derived from pooled human plasma that provides broad immune protection. This is used to manage conditions such as primary and secondary immunodeficiency diseases and neurological and hematological autoimmune conditions.

The market is expected to grow significantly during the forecast period with the rising prevalence of immune-related diseases and increasing research and development activities to launch advanced, easy-to-use dosage forms.

• For instance, in July 2024, Grifols, S.A. announced that the U.S. FDA approved an expanded label for XEMBIFY, i.e., 20% subcutaneous immunoglobulin (SCIg), for the treatment of primary humoral immunodeficiencies (PI). Such advancements are expected to propel the market growth.

Polyvalent Immunoglobulins Market Driver

Rising Prevalence of Autoimmune and Neurological Conditions to Boost Market Growth

The surging cases of autoimmune diseases and neurological conditions, such as Myasthenia gravis, Guillain–Barré syndrome (GBS), are increasing the demand for polyvalent immunoglobulin, beyond immunodeficiency diseases.

• For instance, according to the Myasthenia Gravis Foundation Of America, Inc. in 2024, globally around 150 to 200 out of a million people had myasthenia gravis and 37 out of every 100,000 people had myasthenia gravis in the U.S.

Download Free sample to learn more about this report.

According to the Myasthenia Gravis report, most patients are found in North America and the lowest in Asia.

Polyvalent Immunoglobulins Market Restraint

Limited Plasma Supply and High Production Cost to Hamper Market Growth

As these products are derived from human plasma, the limited availability of sourced plasma is elevating manufacturing costs and increasing the finished product prices, collectively hampering the market growth.

Polyvalent Immunoglobulins Market Opportunity

Emergence of Self-Administration Therapy to Offer Lucrative Growth Opportunity

The rising focus of key players to increase the flexibility and deliver effective treatment to patients with the help of self-administration is increasing the adoption of the drugs. These factors are likely to cater to the market growth.

• For instance, in April 2023, CSL launched a 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) to treat PI and CIDP.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/ Regions, 2024
• Key Industry Developments (Mergers, Acquisitions, Collaborations, and Others)
• Supply Chain Analysis
• Pipeline Analysis
• Overview: Technological Advancements in the Market
• Regulatory & Reimbursement Scenario, By Key Countries/ Regions
• Economic Cost Burden for the Treatment of Key Diseases

Analysis by Product

The market is subdivided into PRIVIGEN, OCTAGAM, GAMMAGARD Liquid, Gamunex-C, Hizentra, XEMBIFY, and others based on product.

The GAMMAGARD liquid segment dominated the market. The dominant share is due to product approval and the presence of extended application areas and availability, which is contributing to the segment’s growth.

• For instance, in June 2025, Takeda Pharmaceutical Company Limited announced that the U.S. FDA had approved GAMMAGARD LIQUID ERC as a replacement therapy in PI.

Analysis by Indication

On the basis of indication, the market is categorized into Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Immune Thrombocytopenic Purpura (ITP), dermatomyositis, and others.

The Primary Immunodeficiency (PI) segment held a significant share of the market. This is due to the rising prevalence of primary immunodeficiency and the presence of a wide range of products for the treatment.

• For instance, in October 2025, Biotest AG launched Yimmugo in the U.S. It is an intravenous polyvalent human normal immunoglobulin (IVIg) to treat primary immunodeficiencies.

Analysis by Route of Administration

The market, in terms of route of administration, is subdivided into intravenous, subcutaneous, and intramuscular.

The intravenous segment held a significant market share. The broad adoption of IV formulation in hospitals and infusion centers for rapid therapeutic response in chronic conditions are propelling the segmental expansion.

• For example, Yimmugo, a product for treating PI, is given intravenously.

Analysis by Distribution Channel

Based on the distribution channel, the market is fragmented into hospital pharmacy, specialty pharmacy, and others.

The hospital pharmacy segment held the maximum share of the market. The increasing adoption of polyvalent immunoglobulin in these settings, as it requires medical supervision and controlled environments, is propelling segmental expansion.

• For instance, in April 2025, the NHS initiated a new framework for the adequate supply of immunoglobulin products across the U.K. and Scotland.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of geography, has been studied across five regions: North America, Europe, Latin America, the Middle East & Africa, and Asia Pacific.

North America accounted for an estimated 60% share of the global polyvalent immunoglobulins market in 2024. This is due to the presence of advanced fractionation facilities and a strong regulatory environment. In addition, the presence of key market players with advanced product offerings bolsters the market growth in the region.

• For instance, as per the Immune Deficiency Foundation, the U.S. has robust advocacy programs that focus on the primary immunodeficiency (PI) community issues.

Europe holds a considerable share of the polyvalent immunoglobulin market. The presence of adequate government facilities and focus on reliable product availability are expected to propel the regional market growth.

Moreover, the Asia Pacific market is expected to grow with a significant CAGR during the forecast period. Increasing focus on developing plasma-derived products and plasma fractionation will boost the market's growth in the region.

Key Players Covered

The global polyvalent immunoglobulins market is highly consolidated, with few major standalone providers.

The report includes the profiles of the following key players:

• CSL (Australia)
• Grifols, S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Bio Products Lab (U.K.)
• Octapharma AG (Switzerland)
• Kedrion Biopharma (Italy)
• LFB (France)

Key Industry Developments

• September 2025: Kedrion Biopharma received approval for QIVIGY from the U.S. FDA. It is an IV immune globulin for treating adults with primary humoral immunodeficiency.
• January 2024: Takeda Pharmaceutical Company Limited announced that the U.S. FDA approved HYQVIA to treat chronic inflammatory demyelinating polyneuropathy (CIDP).